Endotoxin Absorption Therapy

  • Kent Doi


  • Endotoxin (lipopolysaccharide, LPS), a component of the gram-negative bacterial cell wall, is recognized as the most potent microbial mediator implicated in the pathogenesis of sepsis.

  • Removal of circulating endotoxin by hemoperfusion through an immobilized polymyxin B (PMX-B) column (direct hemoperfusion with PMX-B column; PMX-DHP) reportedly improves outcomes in cases of sepsis[1].


Systemic Inflammatory Response Syndrome Endotoxin Absorption Idiopathic Interstitial Pneumonia Endotoxin Activity Endotoxin Activity Assay 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, Lentini P, Nalesso F, Ueno T, Ranieri VM, Ronco C (2007) Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 11:R47PubMedCrossRefGoogle Scholar
  2. 2.
    Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ (1992) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874CrossRefGoogle Scholar
  3. 3.
    Taveira da Silva AM, Kaulbach HC, Chuidian FS, Lambert DR, Suffredini AF, Danner RL (1993) Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med 328:1457–1460PubMedCrossRefGoogle Scholar
  4. 4.
    Wang Y, Liu Y, Sarker KP, Nakashima M, Serizawa T, Kishida A, Akashi M, Nakata M, Kitajima I, Maruyama I (2000) Polymyxin B binds to anandamide and inhibits its cytotoxic effect. FEBS Lett 470:151–155PubMedCrossRefGoogle Scholar
  5. 5.
    Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C (2009) Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301:2445–2452PubMedCrossRefGoogle Scholar
  6. 6.
    Kida Y (2009) Polymyxin B hemoperfusion and mortality in abdominal septic shock. JAMA 302:1969 (Author reply 1969–1970)PubMedCrossRefGoogle Scholar
  7. 7.
    Romaschin AD, Harris DM, Ribeiro MB, Paice J, Foster DM, Walker PM, Marshall JC (1998) A rapid assay of endotoxin in whole blood using autologous neutrophil dependent chemiluminescence. J Immunol Methods 212:169–185PubMedCrossRefGoogle Scholar
  8. 8.
    Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, Opal S, Abraham E, Brett SJ, Smith T, Mehta S, Derzko A, Romaschin A (2004) Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 190:527–534PubMedCrossRefGoogle Scholar
  9. 9.
    Nakamura T, Kawagoe Y, Ueda Y, Koide H (2005) Polymyxin B-immobilized fiber hemoperfusion with low priming volume in an elderly septic shock patient with marked endotoxemia. ASAIO J 51:482–484PubMedCrossRefGoogle Scholar
  10. 10.
    Seo Y, Abe S, Kurahara M, Okada D, Saito Y, Usuki J, Azuma A, Koizumi K, Kudoh S (2006) Beneficial effect of polymyxin B-immobilized fiber column (PMX) hemoperfusion treatment on acute exacerbation of idiopathic pulmonary fibrosis. Intern Med 45:1033–1038PubMedCrossRefGoogle Scholar
  11. 11.
    Kushi H, Miki T, Okamaoto K, Nakahara J, Saito T, Tanjoh K (2005) Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation. Crit Care 9:R653–R661PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2014

Authors and Affiliations

  1. 1.Department of Emergency and Critical Care MedicineUniversity Hospital, The University of TokyoTokyoJapan

Personalised recommendations